Clinical Trial Update: Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) [Phase 1, Phase 2]

View source ↗

Summary

An update on a phase 1/2 trial evaluating selinexor as a single agent and in combination with imatinib for metastatic and/or unresectable gastrointestinal strom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib (imatinib)
• Selinexor (selinexor)

Snippet

Sponsor: Grupo Espanol de Investigacion en Sarcomas | Conditions: Maximum Tolerated Dose, GIST | Phase 1, Phase 2 | Status: UNKNOWN